TCMNPs can not only target tumors through T-cell membrane-initiating proteins and kill cancer cells by releasing anticancer molecules and inducing Fas ligand-mediated apoptosis, but also resist cancer by eliminating TGF-β1 and PD-L1 [68]. This evidence concerns the gene FASLG and cancer.